Aktienanalyse zu Alto Neuroscience Inc (ANRO)ANROAlto Neuroscience Inc

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Alto Neuroscience Inc (ANRO) is not a strong buy. The stock is priced at $24.37, which is below the average analyst price target of $30.75, but it has a low RSI of 31.515 indicating it is oversold. However, the company is facing significant losses with a net income of -$27.6 million in the last quarter, which raises concerns about its financial health. The main risk is the ongoing negative earnings trend, with a projected EPS of -0.80 for Q1 2026, which could further impact investor sentiment.